Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? - PubMed (original) (raw)

Review

Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?

Anna R Carta et al. Neurotox Res. 2013 Feb.

Abstract

A dysregulated response of the neuroimmune system is a main contributor to the progression of neurodegeneration in Parkinson's disease (PD). Recent findings suggest that protracted activating stimuli including α-synuclein, drive microglia to acquire maladaptive functions and to assume a harmful phenotype that prevail over a restorative one. Based on this concept, disease-modifying drugs should be aimed at targeting suppression of harmful-activated microglia and the associated production of neurotoxic molecules as pro-inflammatory cytokines, while sparing or inducing beneficial-activated microglia. In this study, we review current evidence in support of the beneficial effect of targeting peroxisome-proliferator-activated receptor (PPAR)-γ to achieve neuroprotection in PD. PPAR-γ agonists as rosiglitazone and pioglitazone are currently gaining increasing attention as promising disease-modifying drugs in this disorder. Early in vitro studies, followed by studies in in vivo models of PD, have provided convincing evidence that these drugs inhibit neuronal degeneration likely by selectively targeting the expression of neurotoxic factors in reactive microglia. Potential therapeutic application has been corroborated by recent report of pioglitazone neuroprotective activity in a non-human primate model of PD. All together, preclinical evidence have prompted the translation of pioglitazone to a phase II clinical trial in early PD.

PubMed Disclaimer

Cited by

Alterations in neuronal morphology and synaptophysin expression in the rat brain as a result of changes in dietary n-6: n-3 fatty acid ratios.
Hajjar T, Goh YM, Rajion MA, Vidyadaran S, Li TA, Ebrahimi M. Hajjar T, et al. Lipids Health Dis. 2013 Jul 26;12:113. doi: 10.1186/1476-511X-12-113. Lipids Health Dis. 2013. PMID: 23886338 Free PMC article.
Microglial polarization in TBI: Signaling pathways and influencing pharmaceuticals.
Li YF, Ren X, Zhang L, Wang YH, Chen T. Li YF, et al. Front Aging Neurosci. 2022 Aug 1;14:901117. doi: 10.3389/fnagi.2022.901117. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35978950 Free PMC article. Review.
Central role of microglia in sepsis-associated encephalopathy: From mechanism to therapy.
Yan X, Yang K, Xiao Q, Hou R, Pan X, Zhu X. Yan X, et al. Front Immunol. 2022 Jul 26;13:929316. doi: 10.3389/fimmu.2022.929316. eCollection 2022. Front Immunol. 2022. PMID: 35958583 Free PMC article. Review.
Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.
Segura-Aguilar J, Kostrzewa RM. Segura-Aguilar J, et al. Neurotox Res. 2015 Apr;27(3):328-54. doi: 10.1007/s12640-015-9519-y. Epub 2015 Jan 29. Neurotox Res. 2015. PMID: 25631236
Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes.
Lisco G, De Tullio A, Iovino M, Disoteo O, Guastamacchia E, Giagulli VA, Triggiani V. Lisco G, et al. Biomedicines. 2023 Nov 7;11(11):2993. doi: 10.3390/biomedicines11112993. Biomedicines. 2023. PMID: 38001993 Free PMC article. Review.

References

1. Front Biosci. 2008 Jan 01;13:1813-26 - PubMed
1. J Biol Chem. 2005 Jun 3;280(22):21453-62 - PubMed
1. J Neurochem. 2009 Sep;110(5):1617-27 - PubMed
1. J Pharmacol Exp Ther. 2007 Mar;320(3):1002-12 - PubMed
1. J Neuroimmunol. 2009 Nov 30;216(1-2):122-5 - PubMed

Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? - PubMed (original) (raw)